Item 2.02. Results of Operations and Financial Condition.
On November 4, 2019, Iovance Biotherapeutics, Inc. (the "Company") issued a
press release announcing its financial results for the quarter ended September
30, 2019 and an update on recent developments. A copy of that press release is
furnished as Exhibit 99.1.
The information furnished under this Item 2.02, including the accompanying
Exhibit 99.1, shall not be deemed to be "filed" for the purposes of Section 18
of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise
subject to the liability of such section, nor shall such information be deemed
to be incorporated by reference in any subsequent filing by the Company under
the Securities Act of 1933, as amended, or the Exchange Act, regardless of the
general incorporation language of such filing, except as specifically stated in
Item 9.01. Financial Statements and Exhibits.
Exhibit No. Description
99.1 Press Release of Iovance Biotherapeutics, Inc., dated November 4,
© Edgar Online, source Glimpses